Review



hla dqa2  (ProSci Incorporated)


Bioz Verified Symbol ProSci Incorporated is a verified supplier
Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    ProSci Incorporated hla dqa2
    The hazard rate of genes for glioma patients with IDH1mt.
    Hla Dqa2, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hla-dqa2+antibody/HLA-DQA2+Antibody/pmc09500319-141-6-11
    Average 91 stars, based on 1 article reviews
    hla dqa2 - by Bioz Stars, 2026-09
    91/100 stars

    Images

    1) Product Images from "A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy"

    Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2022.1001381

    The hazard rate of genes for glioma patients with IDH1mt.
    Figure Legend Snippet: The hazard rate of genes for glioma patients with IDH1mt.

    Techniques Used:

    Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of IDH1mt-glioma patients. (C) Multivariate Cox regression analysis of HLA-DQA2 , HOXA3 , and SAA2. These three genes were used to construct the risk model.
    Figure Legend Snippet: Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of IDH1mt-glioma patients. (C) Multivariate Cox regression analysis of HLA-DQA2 , HOXA3 , and SAA2. These three genes were used to construct the risk model.

    Techniques Used: Construct

    Expression of HLA-DQA2 , HOXA3 , SAA2 , CD86 , and CD8 in IDH1mt-glioma tissues. IDH1mt-glioma tissues were divided into long- and short-term survival groups according to the patient’s number of days of survival with the cut-off as 15 months. (A) The IHC score of HLA-DQA2 , HOXA3 , and SAA2 in IDH1mt-glioma tissues in long- and short-term groups. (B) Representative figures of expression of HLA-DQA2 , HOXA3 , and SAA2 in long- and short-term group IDH1mt-glioma tissues. (C) Expression of CD86 and CD8 in long- and short-term group IDH1mt-glioma tissues. (D–F) The diagnostic value of HLA-DQA2 , HOXA3 , and SAA2 for distinguishing long- and short-term survival of IDH1mt-glioma patients. ** P < 0.01.
    Figure Legend Snippet: Expression of HLA-DQA2 , HOXA3 , SAA2 , CD86 , and CD8 in IDH1mt-glioma tissues. IDH1mt-glioma tissues were divided into long- and short-term survival groups according to the patient’s number of days of survival with the cut-off as 15 months. (A) The IHC score of HLA-DQA2 , HOXA3 , and SAA2 in IDH1mt-glioma tissues in long- and short-term groups. (B) Representative figures of expression of HLA-DQA2 , HOXA3 , and SAA2 in long- and short-term group IDH1mt-glioma tissues. (C) Expression of CD86 and CD8 in long- and short-term group IDH1mt-glioma tissues. (D–F) The diagnostic value of HLA-DQA2 , HOXA3 , and SAA2 for distinguishing long- and short-term survival of IDH1mt-glioma patients. ** P < 0.01.

    Techniques Used: Expressing, Diagnostic Assay

    Related Articles

    other:

    Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy
    Article Snippet: obtained from all participants. Immunohistochemistry (IHC) staining was performed as described in our previous study ( 15 ). Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, C



    Similar Products

    rabbit polyclonal anti hla dqa2 antibody  (Danaher Inc)
    86
    Danaher Inc rabbit polyclonal anti hla dqa2 antibody
    Rabbit Polyclonal Anti Hla Dqa2 Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hla-dqa2+antibody/pm34955228-51-49-54
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal anti hla dqa2 antibody - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    hla dqa2  (ProSci Incorporated)
    91
    ProSci Incorporated hla dqa2
    The hazard rate of genes for glioma patients with IDH1mt.
    Hla Dqa2, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hla-dqa2+antibody/HLA-DQA2+Antibody/pmc09500319-141-6-11
    Average 91 stars, based on 1 article reviews
    hla dqa2 - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    hla dqa2 antibody  (Bio-Techne corporation)
    90
    Bio-Techne corporation hla dqa2 antibody
    The hazard rate of genes for glioma patients with IDH1mt.
    Hla Dqa2 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hla-dqa2+antibody/HLA+DQA2+Antibody/bio-techne+corporation___nbp1-52094
    Average 90 stars, based on 1 article reviews
    hla dqa2 antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The hazard rate of genes for glioma patients with IDH1mt.

    Journal: Frontiers in Immunology

    Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

    doi: 10.3389/fimmu.2022.1001381

    Figure Lengend Snippet: The hazard rate of genes for glioma patients with IDH1mt.

    Article Snippet: Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, China), and CD86 (1:250; Cat No. ab220188, Abcam).

    Techniques:

    Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of IDH1mt-glioma patients. (C) Multivariate Cox regression analysis of HLA-DQA2 , HOXA3 , and SAA2. These three genes were used to construct the risk model.

    Journal: Frontiers in Immunology

    Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

    doi: 10.3389/fimmu.2022.1001381

    Figure Lengend Snippet: Hub genes selected to construct the risk model. (A, B) LASSO analysis for hub genes associated with the survival rate of IDH1mt-glioma patients. (C) Multivariate Cox regression analysis of HLA-DQA2 , HOXA3 , and SAA2. These three genes were used to construct the risk model.

    Article Snippet: Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, China), and CD86 (1:250; Cat No. ab220188, Abcam).

    Techniques: Construct

    Expression of HLA-DQA2 , HOXA3 , SAA2 , CD86 , and CD8 in IDH1mt-glioma tissues. IDH1mt-glioma tissues were divided into long- and short-term survival groups according to the patient’s number of days of survival with the cut-off as 15 months. (A) The IHC score of HLA-DQA2 , HOXA3 , and SAA2 in IDH1mt-glioma tissues in long- and short-term groups. (B) Representative figures of expression of HLA-DQA2 , HOXA3 , and SAA2 in long- and short-term group IDH1mt-glioma tissues. (C) Expression of CD86 and CD8 in long- and short-term group IDH1mt-glioma tissues. (D–F) The diagnostic value of HLA-DQA2 , HOXA3 , and SAA2 for distinguishing long- and short-term survival of IDH1mt-glioma patients. ** P < 0.01.

    Journal: Frontiers in Immunology

    Article Title: A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy

    doi: 10.3389/fimmu.2022.1001381

    Figure Lengend Snippet: Expression of HLA-DQA2 , HOXA3 , SAA2 , CD86 , and CD8 in IDH1mt-glioma tissues. IDH1mt-glioma tissues were divided into long- and short-term survival groups according to the patient’s number of days of survival with the cut-off as 15 months. (A) The IHC score of HLA-DQA2 , HOXA3 , and SAA2 in IDH1mt-glioma tissues in long- and short-term groups. (B) Representative figures of expression of HLA-DQA2 , HOXA3 , and SAA2 in long- and short-term group IDH1mt-glioma tissues. (C) Expression of CD86 and CD8 in long- and short-term group IDH1mt-glioma tissues. (D–F) The diagnostic value of HLA-DQA2 , HOXA3 , and SAA2 for distinguishing long- and short-term survival of IDH1mt-glioma patients. ** P < 0.01.

    Article Snippet: Primary antibodies used were as follows: HLA-DQA2 (1:200; Cat No. 42-669, ProSci, Fort Collins, CO, USA), HOXA3 (1:100; Cat No.ab230879, Abcam, Cambridge, UK), SAA2 (1:500; Cat No. CAU25292; Biomatik, Kitchener, Canada), CD8 (1:4000; Cat No. 66868-1-Ig; Proteintech, Wuhan, China), and CD86 (1:250; Cat No. ab220188, Abcam).

    Techniques: Expressing, Diagnostic Assay